HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.

Abstract
Escherichia coli purine nucleoside phosphorylase (PNP) expressed in tumors converts relatively nontoxic prodrugs into membrane-permeant cytotoxic compounds with high bystander activity. In the present study, we examined tumor regressions resulting from treatment with E. coli PNP and fludarabine phosphate (F-araAMP), a clinically approved compound used in the treatment of hematologic malignancies. We tested bystander killing with an adenoviral construct expressing E. coli PNP and then more formally examined thresholds for the bystander effect, using both MuLv and lentiviral vectoring. Because of the importance of understanding the mechanism of bystander action and the limits to this anticancer strategy, we also evaluated in vivo variables related to the expression of E. coli PNP (level of E. coli PNP activity in tumors, ectopic expression in liver, percentage of tumor cells transduced in situ, and accumulation of active metabolites in tumors). Our results indicate that F-araAMP confers excellent in vivo dose-dependent inhibition of bystander tumor cells, including strong responses in subcutaneous human glioma xenografts when 95 to 97.5% of the tumor mass is composed of bystander cells. These findings define levels of E. coli PNP expression necessary for antitumor activity with F-araAMP and demonstrate new potential for a clinically approved compound in solid tumor therapy.
AuthorsJeong S Hong, William R Waud, Dana N Levasseur, Tim M Townes, Hui Wen, Sylvia A McPherson, Bryan A Moore, Zsuzsa Bebok, Paula W Allan, John A Secrist 3rd, William B Parker, Eric J Sorscher
JournalCancer research (Cancer Res) Vol. 64 Issue 18 Pg. 6610-5 (Sep 15 2004) ISSN: 0008-5472 [Print] United States
PMID15374975 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antimetabolites, Antineoplastic
  • Vidarabine Phosphate
  • fludarabine phosphate
  • Purine-Nucleoside Phosphorylase
Topics
  • Adenoviridae (genetics)
  • Animals
  • Antimetabolites, Antineoplastic (pharmacokinetics, pharmacology)
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Escherichia coli (enzymology, genetics)
  • Genetic Therapy (methods)
  • Genetic Vectors (genetics)
  • Glioma (drug therapy, enzymology, genetics)
  • Humans
  • Lentivirus (genetics)
  • Mice
  • Mice, Nude
  • Moloney murine leukemia virus (genetics)
  • Purine-Nucleoside Phosphorylase (biosynthesis, genetics, metabolism)
  • Transfection (methods)
  • Vidarabine Phosphate (analogs & derivatives, pharmacokinetics, pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: